Drugs / Vvax001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03141463 | Jan → Nov 2017 | cervical cancer, cervical intraepithelial neoplasia grade 2/3 | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06015854 | Mar 2021 → Feb 2024 | cervical intraepithelial neoplasia grade 2/3, human papilloma virus infection | University Medical Center Groningen | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-06-17 | ViciniVax B.V | Results Phase II trial meets end points vicinivax.com ↗
Vvax001 is safe and feasible and shows preliminary clinical effectiveness in patients with HPV16-associated CIN3 lesions. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-06-17 | ViciniVax B.V | Phase II trial meets end points vicinivax.com ↗ |
| 2017-02-03 | ViciniVax B.V | ViciniVax announces first patient treated in Phase I study with immunotherapy Vvax001 for HPV-related precancers and cancer vicinivax.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vvax001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06015854 ↗ |
| Modality | Vaccine | “Vvax001 is a therapeutic cancer vaccine consisting of a replication-incompetent Semliki Forest Virus (SFV) vector encoding HPV-derived tumor antigens.” NCT03141463 ↗ |
| Route | Intramuscular | “The injections will be administered intramuscularly in the upper legs” NCT06015854 ↗ |